Cancer Communications
indexed by SCI
BMC


REVIEW
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Farhoodeh Ghaedrahmati, Nafiseh Esmaeil, Maryam Abbaspour
Cancer Communications 2022 42:
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/30/2022   doi:10.1002/cac2.12394
ORIGINAL ARTICLE
Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial
Qing Lin, Shangyou Zheng, Xianjun Yu, Meifu Chen, Yu Zhou, Quanbo Zhou, Chonghui Hu, Jing Gu, Zhongdong Xu, Lin Wang, Yimin Liu, Qingyu Liu, Min Wang, Guolin Li, He Cheng, Dongkai Zhou, Guodong Liu, Zhiqiang Fu, Yu Long, Yixiong Li, Weilin Wang, Renyi Qin
Cancer Communications 2022 42:
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/29/2022   doi:10.1002/cac2.12399
LETTER TO THE EDITOR
C-terminal variants of the P2X7 receptor are associated with prostate cancer progression and bone metastasis – evidence from clinical and pre-clinical data
Haiping Song, Hector Manuel Arredondo Carrera, Alexandria Sprules, Ying Ji, Tongsong Zhang, Jiepei He, Eleanor Lawrence, Alison Gartland, Jian Luo, Ning Wang
Cancer Communications 2022 42:
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/29/2022   doi:10.1002/cac2.12391
LETTER TO THE EDITOR
Activation mechanisms of clinically distinct B-Raf V600E and V600K mutants
Fuchen Liu, Xiaochen Feng, Jin Du, Minghao Ruan, Hui Liu
Cancer Communications 2022 42:
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/26/2022   doi:10.1002/cac2.12395
LETTER TO THE EDITOR
Serologic status and safety of inactivated Covid-19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection
Fuchen Liu, Xiaochen Feng, Jin Du, Minghao Ruan, Hui Liu
Cancer Communications 2022 42:
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/24/2022   doi:10.1002/cac2.12398
REVIEW
Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives
Zengli Fang, Qingcai Meng, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Chen Liang, Jie Hua, Yingjun Zhao, Xianjun Yu, Si Shi
Cancer Communications 2022 42:
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/24/2022   doi:10.1002/cac2.12392
ORIGINAL ARTICLE
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin
Yuanyuan Zhao, Bing Zhao, Gang Chen, Yinlan Chen, Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li, Yuefen Zhou, Biyong Ren, Yanda Lu, Jianhua Chen, Zhenteng Liu, Zhenzhong Su, Wenliang Wang, Li Zhang
Cancer Communications 2022 42:
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/22/2022   doi:10.1002/cac2.12397
REVIEW
Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors
Fei Liu, Zixian Wang, Xiaofan Li, Zhen Zhang, Yue Yang, Junquan Chen, Dinghua Chen, Lingling Wu, Xiangyu Liu, Sujun Han, Fangming Wang, Wasilijiang Wahafu, Yibo Gao, Shancheng Ren, Nianzeng Xing, Guangyan Cai, Xiangmei Chen
Cancer Communications 2022 42:
[Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/17/2022   doi:10.1002/cac2.12396
ORIGINAL ARTICLE
Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?
Ruimei Feng, Qingling Su, Xiaoyin Huang, Til Basnet, Xin Xu, Weimin Ye
Cancer Communications 2022 42:
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/17/2022   doi:10.1002/cac2.12393
REVIEW
Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions
Yu-Fei Chen, Ying-ying Xu, Zhi-Ming Shao, Ke-Da Yu
Cancer Communications 2022 42:
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/10/2022   doi:10.1002/cac2.12387

<<    Page 1 of 56  >>    




CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China